EUCTR2013-002343-29-HU进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia - ODYSSEY CHOICE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 803
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women > age 18 or legal age of majority with elevated LDL-C.
- •2. Patients not having adequate control of their hypercholesterolemia, defined according to the most recent NCEP-ATP guidelines at study start, based on their individual level of CVD risk (Appendix 3). Patients who are not on statin therapy must be at moderate CVD risk and must have LDL-C less than or equal to 190 mg/dL (=4.91 mmol/L). However, patients for whom statin therapy is not considered appropriate may be at moderate, high, or very high CVD risk and must have LDL-C less than or equal to 250 mg/dL (=6.47 mmol/L).
- •3. If on statin therapy, patients on the following medications/doses for at least 28 days prior to the screening visit are allowed: atorvastatin 40 mg or 80 mg, rosuvastatin 20 mg or 40 mg, or simvastatin 80 mg (must be on stable dose of simvastatin for at least 1 year), or their maximally tolerated dose of 1 of these 3 statins.
- •4. Willing and able to comply with clinic visits and study-related procedures.
- •5. Provide signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 525
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 175
排除标准
- •1. Patient with homozygous FH (clinically or by previous genotyping)
- •2. Currently taking a statin that is not atorvastatin, rosuvastatin, or simvastatin
- •3. Use of fibrates other than fenofibrate within 6 weeks of the screening visit
- •4. Use of allowed LMTs (eg, omega-3 fatty acids, cholesterol absorption inhibitors [eg, ezetimibe], bile acid resins, niacin, and plant stanols/sterols [such as those found in Benecol®, flax seed oil, or psyllium]) that have not been at a stable dose/regimen for at least 4 weeks prior to the screening visit
- •5. Use of nutraceutical products or over-the-counter therapies that may affect lipids and that have not been at a stable dose/amount for at least 4 weeks prior to the screening visit
- •6. Use of red yeast rice products within 4 weeks of the screening visit or between screening and randomization visits
- •7. Uncontrolled hypothyroidism
- •8. Uncontrolled blood pressure (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg) at the screening visit
- •9. Patient who has received plasmapheresis treatment within 2 months prior to the screening visit, or has plans to receive it during the study
- •10. Recent (within 3 months prior to the screening visit) myocardial infarction, unstable angina leading to hospitalization, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
- •11. Planning to undergo scheduled PCI, CABG, or carotid or peripheral revascularization during the study
- •12. Known history of a hemorrhagic stroke
- •13. History of New York Heart Association Class III or IV heart failure within 12 months prior to the screening visit.
- •14. Newly diagnosed diabetes (within 3 months prior to the screening visit) or poorly controlled diabetes (hemoglobin A1c [HbA1c] >9% at the screening visit)
- •15. History of bariatric surgery within 12 months prior to the screening visit
- •16. Unstable weight, defined by a variation >5 kg within 2 months prior to the screening visit
- •17. Known history of loss of function of PCSK9 (ie, genetic mutation or sequence variation)
- •18. Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to randomization
- •19. Use of continuous estrogen or testosterone hormone replacement therapy, unless the regimen has been stable for 6 weeks prior to the screening visit and there are no plans to change the regimen during the study
- •20. History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
- •21. Known history of positive test for human immunodeficiency virus (HIV)
- •22. Has been previously treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in other clinical studies
- •23. Has taken any active investigational drugs within 1 month or 5 half-lives, whichever is longer; however, patients who have taken anti-PCSK9 therapy at any time are excluded
- •24. Conditions/situations such as:
- •? Any clinically significant abnormality identified at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrain assessment of endpoints, such as major systemic diseases or patients with short life expecta
研究者
相似试验
进行中（未招募）
1 期
Assessment of efficacy and safety in patients with non-cancer-related pain and opioid-induced constipation.Opioid-induced constipation (OIC)EUCTR2011-001987-24-SKAstraZeneca AB630
进行中（未招募）
1 期
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003158-18-ESBiogen Idec Research Limited290
进行中（未招募）
1 期
A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha-1 Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2013-001870-38-SEGrifols Therapeutics Inc.339
进行中（未招募）
1 期
A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)Prurigo NodularisMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858EUCTR2019-004789-17-FRGalderma S.A.240
招募中
3 期
Chronic Migraine in Patients 12 to 17 Years of AgeCTRI/2021/07/034818Eli Lilly and Company India Pvt Ltd